Time To Fix The FDA Weight Loss Mistake

It is hard to miss the results of the miracle-like treatments for obesity and diabetes. The rise of semaglutide (AKA GLP-1) medications has been a game changer for many families and communities. However, a recent decision by unelected bureaucrats left by the Biden Administration at the FDA could undermine this transformation.

Over the past two years, the soaring demand for semaglutide, driven by its effectiveness in treating diabetes and aiding weight loss, outstripped supply. Recognizing this crisis, the FDA allowed alternative health companies to step in and create their own versions of the health agent. These compounded versions provided a lifeline to patients who couldn’t afford the sky-high prices of the brand-name drugs or who simply couldn’t find them due to supply shortages.

But three weeks ago, Biden leftovers at the FDA declared the shortage over, barring these compounded alternatives from continuing in the market. This means that consumers who rely on these lower-cost options are suddenly out of luck — forced back into a market dominated by Ozempic and Wegovy, which hold near-total pricing power.

The compounded semaglutide options carry a less than $200 per month price tag, hundreds of dollars cheaper than the name brands. Now that they are no longer allowed to fill the supply gap, consumers are left with only one option: pay whatever the makers of Ozempic and WeGovy charge. And if history is any guide, prices won’t come down anytime soon. The current list price for Ozempic is around $900 per month, while Wegovy soars even higher at approximately $1,300 per month. As reported by The Blaze, this FDA ruling effectively makes Ozempic even more expensive for consumers.

Many insurance plans either don’t cover these medications or have stringent requirements that make access difficult. Without compounded alternatives, uninsured and even middle class patients will face impossible financial burdens. The likely outcome? Many will be forced to forgo treatment altogether, leading to worsening health conditions and higher long-term healthcare costs.

Beyond affordability, access is a key concern. Many patients, especially those in rural or underserved areas, relied on compounding option when brand-name options were unavailable. The recent FDA decision disproportionately harms these communities, forcing them into an already overburdened healthcare system where access to specialists and pharmacies carrying the treatment may be limited.

The impact of the FDA’s ruling isn’t just theoretical, it is already playing out in the marketplace. Telehealth companies like Hims & Hers, which offered compounded semaglutide, have announced they will no longer be able to provide it. In response, their stock plummeted 27% overnight, illustrating just how dependent consumers were on this alternative supply.

The biggest beneficiary of the FDA’s decision is, without a doubt, the makers of Ozempic and WeGovy, which is the Danish pharma titan, Novo Nordisk. As Aiden Buzzetti points out in Blaze, “Americans deserve access to affordable, life-changing medications without being forced to bankroll Denmark’s economic success.”

By eliminating competition from compounded semaglutide, the company ensures that consumers have no alternative but to buy its high-priced products. As Sean Spicer recently noted “increasing access to life-changing medications should be our government’s priority. So why did the Biden administration put the profits of Big Pharma over the well-being of millions of Americans?”

The impact of the FDA’s ruling isn’t just theoretical; it is already playing out in the marketplace. Telehealth companies like Hims & Hers, which offered compounded semaglutide, have announced they will no longer be able to provide it. In response, their stock plummeted 27% overnight, illustrating just how dependent consumers were on this alternative supply. As Blaze highlights, small pharmacies have accused the FDA of favoring Big Pharma over consumers in this decision.

The FDA’s decision made by Biden holdovers is a bigtime mistake and consumers will bear the entire burden. If the goal was to ensure access to safe, regulated semaglutide, then a better approach would have been to allow compounding pharmacies to continue offering alternatives until prices stabilized and widespread availability was truly secured.

The Trump FDA should immediately reevaluate the shortage decision. By reversing the ban, the agency can change the bottom line for consumers who are now priced out of this medication. Until then, millions of Americans who rely on semaglutide are left with an impossible choice: pay exorbitant prices or go without life-changing treatment. The FDA’s decision is not just a setback, it’s a disaster for those trying to get their health right.